Recent Reports from University of South Alabama Highlight Findings in Pancreatic Cancer [Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic ...]
By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Oncology are presented in a new report. According to news reporting originating in Mobile, Alabama, by NewsRx journalists, research stated, "MicroRNAs are small (18-22 nucleotide long) noncoding RNAs that play important roles in biological processes through posttranscriptional regulation of gene expression. Their aberrant expression and functional significance are reported in several human malignancies, including pancreatic cancer."
The news reporters obtained a quote from the research from the University of South Alabama, "Recently, we identified miR-150 as a novel tumor suppressor microRNA in pancreatic cancer. Furthermore, expression of miR-150 was downregulated in the majority of tumor cases, suggesting that its restoration could serve as an effective approach for pancreatic cancer therapy. In the present study, we developed a nanoparticle-based miR-150 delivery system and tested its therapeutic efficacy in vitro. Using double emulsion solvent evaporation method, we developed a poly (D,L-lactide-co-glycolide) (PLGA)-based nanoformulation of miR-150 (miR-150-NF). Polyethyleneimine (a cationic polymer) was incorporated in PLGA matrix to increase the encapsulation of miR-150. Physical characterization of miR-150-NF demonstrated that these nanoparticles had high encapsulation efficiency (~78%) and exhibited sustained release profile. Treatment of pancreatic cancer cells with miR-150-NF led to efficient intracellular delivery of miR-150 mimics and caused significant downregulation of its target gene (MUC4) expression. Inhibition of MUC4 correlated with a concomitant decrease in the expression of its interacting partner, HER2, and repression of its downstream signaling. Furthermore, treatment of pancreatic cancer cells with miR-150-NF suppressed their growth, clonogenicity, motility, and invasion."
According to the news reporters, the research concluded: "Together, these findings suggest that PLGA-based nanoformulation could potentially serve as a safe and effective nanovector platform for miR-150 delivery to pancreatic tumor cells."
For more information on this research see: Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. International Journal of Nanomedicine, 2014;9():2933-42 (see also Oncology).
Our news correspondents report that additional information may be obtained by contacting S. Arora, Dept. of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, United States. Additional authors for this research include S.K. Swaminathan, A. Kirtane, S.K. Srivastava, A. Bhardwaj, S. Singh, J. Panyam and A.P Singh.
Keywords for this news article include: Mobile, Alabama, Therapy, Oncology, United States, Gastroenterology, Pancreatic Cancer, Pancreatic Neoplasms, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC